The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
Publications found:
8,499
Sort by:
Sclerostin (SOST) - Drugs in Development, 2021
US$ 3,000.00
Sclerostin (SOST) - Drugs in Development, 2021 SUMMARY Sclerostin (SOST) - Drugs in Development, 2021 provides in depth analysis on Sclerostin (SOST) targeted pipeline therapeutics. The report provide...
April 2021
35 pages
Sepsis (Infectious Disease) - Drugs in Development, 2021
US$ 2,500.00
Sepsis (Infectious Disease) - Drugs in Development, 2021 SUMMARY Sepsis (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Sepsis pipeline landscape. The report provides com...
April 2021
230 pages
Septic Shock (Other Diseases) - Drugs in Development, 2021
US$ 2,000.00
Septic Shock (Other Diseases) - Drugs in Development, 2021 SUMMARY Septic Shock (Other Diseases) - Drugs in Development, 2021 provides an overview of the Septic Shock pipeline landscape. The report pr...
April 2021
50 pages
Serum Albumin (ALB) - Drugs in Development, 2021
US$ 3,000.00
Serum Albumin (ALB) - Drugs in Development, 2021 SUMMARY Serum Albumin (ALB) - Drugs in Development, 2021 provides in depth analysis on Serum Albumin (ALB) targeted pipeline therapeutics. The report p...
April 2021
30 pages
Sezary Syndrome (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Sezary Syndrome (Oncology) - Drugs in Development, 2021 SUMMARY Sezary Syndrome (Oncology) - Drugs in Development, 2021 provides an overview of the Sezary Syndrome pipeline landscape. The report provi...
April 2021
55 pages
Sirtuin (SIRT or EC 2.3.1.) - Drugs in Development, 2021
US$ 3,000.00
Sirtuin (SIRT or EC 2.3.1.) - Drugs in Development, 2021 SUMMARY Sirtuin (SIRT or EC 2.3.1.) - Drugs in Development, 2021 provides in depth analysis on Sirtuin (SIRT or EC 2.3.1.) targeted pipeline th...
April 2021
30 pages
Skin Infections (Dermatology) - Drugs in Development, 2021
US$ 2,000.00
Skin Infections (Dermatology) - Drugs in Development, 2021 SUMMARY Skin Infections (Dermatology) - Drugs in Development, 2021 provides an overview of the Skin Infections pipeline landscape. The report...
April 2021
45 pages
Skin Ulcers (Dermatology) - Drugs in Development, 2021
US$ 2,000.00
Skin Ulcers (Dermatology) - Drugs in Development, 2021 SUMMARY Skin Ulcers (Dermatology) - Drugs in Development, 2021 provides an overview of the Skin Ulcers pipeline landscape. The report provides co...
April 2021
30 pages
Sleep Apnea (Respiratory) - Drugs in Development, 2021
US$ 2,000.00
Sleep Apnea (Respiratory) - Drugs in Development, 2021 SUMMARY Sleep Apnea (Respiratory) - Drugs in Development, 2021 provides an overview of the Sleep Apnea pipeline landscape. The report provides co...
April 2021
30 pages
Soft Tissue Sarcoma (Oncology) - Drugs in Development, 2021
US$ 2,500.00
Soft Tissue Sarcoma (Oncology) - Drugs in Development, 2021 SUMMARY Soft Tissue Sarcoma (Oncology) - Drugs in Development, 2021 provides an overview of the Soft Tissue Sarcoma pipeline landscape. The...
April 2021
220 pages